{"nctId":"NCT00839800","briefTitle":"Study to Investigate the Efficacy of Symbicort® SMART.","startDateStruct":{"date":"2009-02"},"conditions":["Asthma"],"count":2091,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Symbicort Turbuhaler"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Symbicort Turbuhaler","Drug: Terbutaline Turbuhaler"]}],"interventions":[{"name":"Symbicort Turbuhaler","otherNames":[]},{"name":"Terbutaline Turbuhaler","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of asthma according to the Global Initiative for Asthma guidelines (GINA) 2007 with a documented history of at least 6 months duration.\n* Reversible airway obstruction, defined as an increase in FEV1 ≥12% relative to baseline for all patients 15-30 minutes after inhalation of in total 2 x 0.4 mg terbutaline Turbuhaler\n* Prescribed use of inhaled glucocorticoid steroid (GCS) (any brand) for at least 12 weeks.\n\nExclusion Criteria:\n\n* Respiratory infection affecting the asthma, as judged by the investigator, within 4 weeks.\n* Intake of oral, rectal or parenteral GCS within 4 weeks and/or depot parenteral GCS within 12 weeks.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study","description":"Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid \\[GCS\\] treatment, hospitalization, or emergency room \\[ER\\] treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Asthma Exacerbations","description":"Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"259","spread":null},{"groupId":"OG001","value":"363","spread":null}]}]}]},{"type":"SECONDARY","title":"Morning Peak Expiratory Flow (PEF)","description":"The mean value from a 52-week treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"331.8","spread":"102.2"},{"groupId":"OG001","value":"324.7","spread":"101.9"}]}]}]},{"type":"SECONDARY","title":"Evening PEF","description":"The mean value from a 52-week treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"334.2","spread":"102.6"},{"groupId":"OG001","value":"327.8","spread":"103.1"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1)","description":"The mean value for Weeks 4, 12, 24, 36 and 52 was analysed.","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.258","spread":"0.76"},{"groupId":"OG001","value":"2.222","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Use of As-needed Medication","description":"The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":"1.39"},{"groupId":"OG001","value":"1.46","spread":"1.60"}]}]}]},{"type":"SECONDARY","title":"Asthma Symptom Score","description":"The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"1.04"},{"groupId":"OG001","value":"1.22","spread":"1.02"}]}]}]},{"type":"SECONDARY","title":"Nights With Awakening(s) Due to Asthma Symptoms","description":"The mean value from the treatment period was presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":"27.1"},{"groupId":"OG001","value":"17.5","spread":"27.2"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations","description":"Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptom-free Days (no Symptoms and no Awakenings)","description":"A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":"37.8"},{"groupId":"OG001","value":"41.6","spread":"37.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of As-needed-free Days","description":"An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":"36.7"},{"groupId":"OG001","value":"47.2","spread":"36.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)","description":"An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":"37.3"},{"groupId":"OG001","value":"37.9","spread":"36.6"}]}]}]},{"type":"SECONDARY","title":"Asthma Control Questionnaire (ACQ)","description":"The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.162","spread":"0.78"},{"groupId":"OG001","value":"1.289","spread":"0.75"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":41,"n":1049},"commonTop":["Nasopharyngitis","Bronchitis","Viral Upper Respiratory Tract Infection","Pharyngitis"]}}}